Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection?

doi:10.4254/wjh.v8.i19.815

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 8, Issue 19

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8406)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-4) series, Tables (1-1) series.

Item

Count

PDF

504

WORD

298

HTML

3129

Figures (1-4)

226

Tables (1-1)

229

Sum=4386

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

379

Download

1035

Sum=1414

Publishing Process of This Article

Item

Count

Browse

1005

Download

1601

Sum=2606

Jul 8, 2016 (publication date) through Nov 22, 2024

Times Cited of This Article

Times Cited (5)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

World J Hepatol. Jul 8, 2016; 8(19): 815-824
Published online Jul 8, 2016. doi: 10.4254/wjh.v8.i19.815

Full Size Figure Download Figure

Figure 4 Evolution of neutrophil gelatinase associated lipocalin (A) and estimated glomerular filtration rate (B) in 8 patients during the first 12 week of hepatitis C virus therapy with directly acting antiviral containing regimens. Number of patients and respective treatment for hepatitis C virus infection are specified. PEG-IFN: Pegylated-interferon; RBV: Ribavirin; TVR: Telaprevir, SMV: Simeprevir; DCV: Daclatasvir; eGFR: Estimated glomerular filtration rate; NGAL: Neutrophil gelatinase associated lipocalin.

Citation: Strazzulla A, Coppolino G, Di Fatta C, Giancotti F, D’Onofrio G, Postorino MC, Mazzitelli M, Mammone SV, Gentile I, Rivoli L, Palella E, Gravina T, Costa C, Pisani V, De Maria V, Barreca GS, Marascio N, Focà A, Fuiano G, Gulletta E, Torti C. Is neutrophil gelatinase associated lipocalin useful in hepatitis C virus infection? World J Hepatol 2016; 8(19): 815-824
URL: https://www.wjgnet.com/1948-5182/full/v8/i19/815.htm
DOI: https://dx.doi.org/10.4254/wjh.v8.i19.815